Abbott Laboratories (ABT) fair value analysis
S&P 500 · Updated 2026-10-19
ABT price how computed
Forward Fair Value verdict
UndervaluedABT is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $99.60
- Sector
- Healthcare
- 12-month range
- $82.56–$130.59
- Market cap
- $172B
- From 52-week high
- -23.7%
- Shares outstanding
- 1.73B
- Rank in Healthcare by discount to fair value
- #26 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Abbott Laboratories is a diversified healthcare company that manufactures and sells pharmaceuticals, medical devices, diagnostics, and nutritional products for human health. The company operates globally across multiple continents, serving healthcare providers, patients, and consumers in countries around the world.
ABT currently ranks #26 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $172B
- P/E (trailing)
- 19x
- Revenue (TTM)
- $46.6B
- Net margin
- 11.6%
- EPS (TTM)
- $5.26
- Gross margin
- 58.0%
- Debt / equity
- 0.64
- Revenue growth (3-yr avg)
- 8.1%
- Shares outstanding
- 1.73B
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Expanding
- 52-week position
- The lower-middle quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 62 · neutral
- 50-day average
- $105.87
- 200-day average
- $102.81
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Dividends how computed
- Paid, last 12 months
- $2.52 per share (4 payments)
- Yield on last price
- 2.53%
- Consecutive years of increases
- 11
- Last ex-dividend date
- 2026-10-15
- Last payment date
- 2026-11-16
Earnings how computed
- Last 8 quarters vs consensus
- 4 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+2.3%)
2026-03 ▬ met (0.0%)
2025-12 ▲ beat (+0.7%)
2025-09 ▬ met (0.0%)
2025-06 ▬ met (0.0%)
2025-03 ▲ beat (+1.9%)
2024-12 ▬ met (0.0%)
2024-09 ▲ beat (+0.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 22 buy · 5 hold · 0 sell (27 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $121
- Target vs last price
- +21.5%
What our data shows for ABT
- Our model validated 17 trailing price-to-earnings windows for ABT, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $82.56–$130.59.
- The 14-day relative strength index sits at a neutral 62.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for ABT
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent ABT news
TickrTrends' derived news-sentiment signal for ABT is currently leaning positive, computed from recent coverage.
- Abbott Laboratories (ABT) Q3 2026 Earnings Call Highlights: Accelerating Growth, Nutrition Spin-Off Plans, and Revised Guidance (gurufocus.com, 2026-10-21)
TickrTrends take: Abbott Laboratories reported accelerating growth in Q3 2026 while announcing plans to spin off its nutrition business and revising guidance upward, developments that align with TickrTrends' current undervalued assessment of the company. The nutrition spin-off could unlock value by allowing investors to separately evaluate two distinct business models within the Healthcare sector, potentially addressing prior valuation constraints from the conglomerate structure. Valuation-focused investors should monitor how the market reprices ABT shares following the separation and whether the revised guidance translates into sustained earnings growth that justifies a higher multiple. - US stocks today: Nasdaq leads Wall Street higher as SpaceX, Super Micro lift AI sentiment (economictimes.indiatimes.com, 2026-10-21)
TickrTrends take: While the broader market rally reflected in today's Nasdaq gains was driven by technology and AI-related momentum, ABT's Healthcare sector positioning places it outside the primary drivers of today's market strength. With TickrTrends currently assessing ABT as undervalued, valuation-focused investors should monitor whether healthcare stocks gain independent momentum or remain decoupled from the AI sentiment lift seen in technology equities. The divergence between sector performance can offer insight into whether ABT's undervalued status reflects a temporary sector rotation or a more persistent valuation opportunity. - Billionaires and Trump Were Buying This Healthcare Stock (insidermonkey.com, 2026-10-19)
TickrTrends take: Abbott Laboratories trades at a valuation that TickrTrends currently assesses as undervalued within the Healthcare sector, creating potential interest from investors seeking price-to-value opportunities. Recent buying activity by high-net-worth individuals and political figures may reflect confidence in the company's fundamentals, though valuation-focused investors should monitor whether such buying patterns sustain or whether the market reprices the stock relative to earnings and cash flow metrics. The combination of perceived undervaluation and notable investor interest suggests ABT warrants continued observation of its financial performance and market positioning within Healthcare.
More ABT news
- ABT Reiterated by TD Cowen -- Price Target Maintained at $135 (gurufocus.com, 2026-10-16)
- Abbott Laboratories is More than a Dividend Stock. Here’s Why. (insidermonkey.com, 2026-10-11)
- US President Donald Trump buys $1 million-plus stakes in Meta, Microsoft, McDonald’s; adds SpaceX debt (economictimes.indiatimes.com, 2026-10-08)
- Trump bought up to $25 million in Meta and millions in SpaceX debt in August (cnbc.com, 2026-10-08)
What people are saying
Follow the ABT conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for ABT show movement in the Relative Strength Index, which shifted from the oversold zone to the neutral zone this week. The current valuation verdict for the healthcare sector stock remains undervalued. This shift in the RSI zone suggests reduced selling pressure compared to the previous week's assessment.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — ABT's technical indicators shifted this week as its Relative Strength Index moved from neutral territory into oversold levels. The stock's current valuation verdict remains Undervalued according to TickrTrends' derived indicators. This oversold condition in the RSI suggests the Healthcare sector stock may have experienced notable downward price momentum during the week.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ABT stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), ABT is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is ABT's TickrTrends verdict?
ABT's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does ABT compare to other Healthcare stocks?
ABT ranks #26 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is ABT overbought or oversold?
ABT's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does ABT pay a dividend?
Yes. ABT paid $2.52 per share over the last twelve months (4 payments), a 2.53% yield on TickrTrends' last price, and has raised the annual total for 11 consecutive years. The last ex-dividend date was 2026-10-15.
Does ABT usually beat earnings estimates?
Over its last 8 reported quarters ABT beat the consensus estimate 4 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ABT?
Of 27 analysts covering ABT, 22 rate it a buy, 5 a hold and 0 a sell - buy-leaning, with a consensus price target of $121 (+21.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
ABT vs AMPH · ABT vs BLLN · ABT vs CI · ABT vs DVA · ABT vs GEHC